SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum — Frank Preston (2024) | RDL Network
SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum
Article 2024 en
Authors
FP
Frank Preston
MA
Matthew Anson
DR
David R. Riley
Abstract
1 min read
In this large-scale real-world study, SGLT2i use was associated with a lower incidence of gout in patients with T2D compared to both insulin and metformin controls. These findings suggest the potential of SGLT2i as a promising therapeutic option for treating gout in this population.
Anna Palomar‐Cros, Bernard Srour, Valentina A. Andreeva, Léopold Fezeu, Alice Bellicha, Emmanuelle Kesse‐Guyot, Serge Hercberg, Dora Romaguera, Manolis Kogevinas, Mathilde Touvier
Diana Nabrdalik-Leśniak, Katarzyna Nabrdalik, Krzysztof Irlik, Oliwia Janota, Hanna Kwiendacz, Paulina Szromek‐Białek, Mirosław Maziarz, Tomasz Stompór, Janusz Gumprecht, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.